Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience
JCO Oncology Practice · 2025
DOI: 10.1200/op.24.00416 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Ivan J Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UW Medicine, Seattle, WA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Tumor Lysis Syndrome. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Venetoclax is the standard of care for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) but requires intensive monitoring for optimal safety. Clinical relevance of intensive monitoring in practice is unknown, especially for patients with low or intermediate risk for tumor lysis syndrome (TLS). PATIENTS AND METHODS A retrospective review was conducted to determine clinical significance of monitoring for TLS during standard ramp-up for patients with CLL/SLL. Patients receiving abbreviated ramp-up, clinical trials, or concurrent Bruton tyrosine kinase inhibitors were excluded. The primary end point was TLS incidence, with secondary end points describing associated clinical interventions. RESULTS Fifty-five patients met study criteria. The majority of patients received venetoclax as first-line therapy (58%), with anti-CD20 antibody therapy (82%), and were at low risk of TLS (75%). No clinical TLS events occurred, whereas laboratory TLS occurred in only 1.8% of patients. No patients required antihyperuricemic therapy, and few interventions for hyperphosphatemia or hypocalcemia (3.6% of patients) were required. Additional intravenous fluids were uncommonly required (1.8% of patients), and no unplanned hospitalizations were required. CONCLUSION These findings support efforts to reduce intensive monitoring requirements during venetoclax ramp-up for patients with CLL, potentially increasing accessibility of venetoclax.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, UW Medicine, Seattle, WA.
- Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA.
- Department of Research, Fred Hutchinson Cancer Center, Seattle, WA.
- Department of Hematology and Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA.
- Division of Hematology and Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
ORCID-Profile: Ivan J Huang, Grace T Baek, Jonathan Cohen, Laura Samples, Stephen D Smith, Edus H Warren, Ajay K Gopal, Ryan C Lynch, Mazyar Shadman
Zitieren
APA
Huang, I. J., Baek, G. T., Cohen, J., Khajaviyan, S., Louie, S., Samples, L., Smith, S. D., Till, B. G., Warren, E. H., Gopal, A. K., Poh, C., Lynch, R. C., Ujjani, C. S., & Shadman, M. (2025). Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience. JCO Oncology Practice. https://doi.org/10.1200/op.24.00416
Vancouver
Huang IJ, Baek GT, Cohen J, Khajaviyan S, Louie S, Samples L, et al. Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience. JCO Oncology Practice. 2025. doi:10.1200/op.24.00416
BibTeX
@article{Huang2025,
author = {Huang, Ivan J and Baek, Grace T and Cohen, Jonathan and Khajaviyan, Sirin and Louie, Stephanie and Samples, Laura and Smith, Stephen D and Till, Brian G and Warren, Edus H and Gopal, Ajay K and Poh, Christina and Lynch, Ryan C and Ujjani, Chaitra S and Shadman, Mazyar},
title = {Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience},
journal = {JCO Oncology Practice},
year = {2025},
doi = {10.1200/op.24.00416}
}
EUVIMED